Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NGVT Stock Summary
In the News
Ingevity's (NGVT) Earnings and Sales Surpass Estimates in Q4
Ingevity (NGVT) sees strong results in the Performance Materials segment and the Road Technologies business line in Q4.
Ingevity (NGVT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Ingevity (NGVT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ingevity (NGVT) Q4 Earnings and Revenues Beat Estimates
Ingevity (NGVT) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to earnings of $0.57 per share a year ago.
Why Is Ingevity (NGVT) Down 8.3% Since Last Earnings Report?
Ingevity (NGVT) reported earnings 30 days ago. What's next for the stock?
Ingevity (NGVT) Extends Distributorship With TRiiSO for Capa
TRiiSO's technical support strengths complement Ingevity's (NGVT) commitment to providing solutions to challenging formulation issues.
Ingevity Corporation (NGVT) Q3 2023 Earnings Call Transcript
Ingevity Corporation (NYSE:NGVT ) Q3 2023 Earnings Conference Call November 2, 2023 10:00 AM ET Company Participants John Nypaver - VP of IR & Treasurer John Fortson - President, CEO & Director Mary Hall - EVP & CFO Richard White - SVP & President, Performance Chemicals Stuart Woodcock - EVP & President, Performance Materials Conference Call Participants Vincent Anderson - Stifel, Nicolaus & Company Jonathan Tanwanteng - CJS Securities John McNulty - BMO Capital Markets Daniel Rizzo - Jefferies Christopher Kapsch - Loop Capital Markets Operator Good morning or good afternoon, and welcome to the Ingevity Third Quarter 2023 Earnings Call and Webcast. My name is Adam, and I'll be your operator for today.
Ingevity's (NGVT) Earnings and Sales Miss Estimates in Q3
Lower volumes due to weak industrial demand hurt Ingevity's (NGVT) Advanced Polymer Technologies and the Industrial Specialties business lines in Q3.
Compared to Estimates, Ingevity (NGVT) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Ingevity (NGVT) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ingevity announces dates for third-quarter 2023 earnings release and webcast
NORTH CHARLESTON, S.C.--(BUSINESS WIRE)--Ingevity announced today that it will release its third-quarter 2023 earnings after the stock market close on Wednesday, November 1, 2023.
Ingevity Corporation: The Risk To Reward Is Currently Favorable
Ingevity Corporation has seen declines in price due to recent earnings and balance sheet risks. Despite the leveraged balance sheet, Ingevity's diversification strategy and undervaluation make it a favorable investment. Analysts rate Ingevity as a "buy" with a 55.89% upside potential, indicating a positive risk-reward ratio.
NGVT Financial details
NGVT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 30.93 | 29.45 | 34.96 | 43.7 | 46.38 | |
Net income per share | 4.39 | 4.39 | 2.97 | 5.54 | -0.15 | |
Operating cash flow per share | 6.6 | 8.53 | 7.36 | 8.2 | 5.62 | |
Free cash flow per share | 3.85 | 5.97 | 4.75 | 4.47 | 2.61 | |
Cash per share | 1.36 | 6.24 | 6.92 | 2.01 | 2.64 | |
Book value per share | 12.7 | 15.67 | 16.93 | 18.29 | 17.3 | |
Tangible book value per share | -7.28 | -4.15 | -2.66 | -5.89 | -7.71 | |
Share holders equity per share | 12.7 | 15.67 | 16.93 | 18.29 | 17.3 | |
Interest debt per share | 31.46 | 32.73 | 33.54 | 40.45 | 40.53 | |
Market cap | 3.65B | 3.13B | 2.85B | 2.69B | 1.72B | |
Enterprise value | 4.82B | 4.14B | 3.83B | 4.1B | 3.16B | |
P/E ratio | 19.88 | 17.24 | 24.16 | 12.71 | -319.14 | |
Price to sales ratio | 2.83 | 2.57 | 2.05 | 1.61 | 1.02 | |
POCF ratio | 13.25 | 8.88 | 9.74 | 8.59 | 8.4 | |
PFCF ratio | 22.7 | 12.69 | 15.08 | 15.76 | 18.08 | |
P/B Ratio | 6.88 | 4.83 | 4.24 | 3.85 | 2.73 | |
PTB ratio | 6.88 | 4.83 | 4.24 | 3.85 | 2.73 | |
EV to sales | 3.73 | 3.4 | 2.75 | 2.46 | 1.87 | |
Enterprise value over EBITDA | 11.68 | 10.4 | 11.35 | 9.09 | 8 | |
EV to operating cash flow | 17.5 | 11.74 | 13.07 | 13.1 | 15.41 | |
EV to free cash flow | 29.98 | 16.78 | 20.23 | 24.05 | 33.17 | |
Earnings yield | 0.05 | 0.06 | 0.04 | 0.08 | 0 | |
Free cash flow yield | 0.04 | 0.08 | 0.07 | 0.06 | 0.06 | |
Debt to equity | 2.39 | 2.02 | 1.91 | 2.13 | 2.19 | |
Debt to assets | 0.59 | 0.56 | 0.52 | 0.54 | 0.53 | |
Net debt to EBITDA | 2.84 | 2.54 | 2.89 | 3.13 | 3.64 | |
Current ratio | 2.15 | 2.81 | 2.7 | 2.24 | 1.81 | |
Interest coverage | 6.99 | 7.05 | 4.77 | 6.31 | 2.72 | |
Income quality | 1.5 | 1.89 | 2.48 | 1.48 | -37.98 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0.02 | 0.02 | 0.04 | 0.02 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Intangibles to total assets | 0.39 | 0.35 | 0.32 | 0.34 | 0.35 | |
Capex to operating cash flow | -0.42 | -0.3 | -0.35 | -0.46 | -0.54 | |
Capex to revenue | -0.09 | -0.09 | -0.07 | -0.09 | -0.06 | |
Capex to depreciation | -1.35 | -1.06 | -0.94 | -1.31 | -0.78 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Graham number | 35.44 | 39.36 | 33.62 | 47.76 | 7.59 | |
ROIC | 0.14 | 0.12 | 0.08 | 0.12 | 0.06 | |
Return on tangible assets | 0.14 | 0.12 | 0.07 | 0.12 | 0 | |
Graham Net | -32.01 | -29.63 | -32.11 | -42.57 | -43.35 | |
Working capital | 247.7M | 405.3M | 456M | 375.5M | 295.7M | |
Tangible asset value | -304.4M | -171.3M | -105.8M | -225M | -281.4M | |
Net current asset value | -1.15B | -1.06B | -1.07B | -1.36B | -1.33B | |
Invested capital | 2.39 | 2.02 | 1.91 | 2.13 | 2.19 | |
Average receivables | 134.45M | 149M | 154.85M | 193.25M | 217.9M | |
Average payables | 96M | 101.65M | 115M | 150.3M | 166.6M | |
Average inventory | 201.95M | 200.75M | 215.1M | 288.1M | 322.4M | |
Days sales outstanding | 42.35 | 44.42 | 42.42 | 49.18 | 45.5 | |
Days payables outstanding | 44.61 | 50.67 | 52.26 | 58.1 | 45.69 | |
Days of inventory on hand | 95.65 | 91.91 | 100.19 | 111.34 | 89.37 | |
Receivables turnover | 8.62 | 8.22 | 8.61 | 7.42 | 8.02 | |
Payables turnover | 8.18 | 7.2 | 6.98 | 6.28 | 7.99 | |
Inventory turnover | 3.82 | 3.97 | 3.64 | 3.28 | 4.08 | |
ROE | 0.35 | 0.28 | 0.18 | 0.3 | -0.01 | |
Capex per share | -2.75 | -2.56 | -2.61 | -3.73 | -3.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 10.26 | 10.56 | 13.25 | 12.31 | 10.27 | |
Net income per share | 0.42 | 1.36 | 0.98 | 0.7 | -3.23 | |
Operating cash flow per share | 2.63 | 0.14 | 1.33 | 2.95 | 1.23 | |
Free cash flow per share | 1.31 | -0.54 | 0.73 | 2.03 | 0.43 | |
Cash per share | 2.05 | 2.1 | 1.87 | 2.33 | 2.67 | |
Book value per share | 18.67 | 19.52 | 19.63 | 19.84 | 17.44 | |
Tangible book value per share | -6.02 | -5.25 | -5.7 | -4.89 | -7.77 | |
Share holders equity per share | 18.67 | 19.52 | 19.63 | 19.84 | 17.44 | |
Interest debt per share | 40.29 | 41.41 | 43.05 | 41.8 | 38.91 | |
Market cap | 2.63B | 2.66B | 2.12B | 1.72B | 1.71B | |
Enterprise value | 4.05B | 4.08B | 3.57B | 3.11B | 3.15B | |
P/E ratio | 42.22 | 13.11 | 14.9 | 17.11 | -3.66 | |
Price to sales ratio | 6.87 | 6.77 | 4.39 | 3.87 | 4.6 | |
POCF ratio | 26.83 | 511.22 | 43.71 | 16.13 | 38.33 | |
PFCF ratio | 53.76 | -131.6 | 79.23 | 23.5 | 111 | |
P/B Ratio | 3.77 | 3.66 | 2.96 | 2.4 | 2.71 | |
PTB ratio | 3.77 | 3.66 | 2.96 | 2.4 | 2.71 | |
EV to sales | 10.55 | 10.4 | 7.42 | 6.97 | 8.47 | |
Enterprise value over EBITDA | 55.3 | 33.38 | 29.36 | 27.02 | 195.49 | |
EV to operating cash flow | 41.22 | 785.18 | 73.82 | 29.09 | 70.57 | |
EV to free cash flow | 82.61 | -202.13 | 133.82 | 42.37 | 204.37 | |
Earnings yield | 0.01 | 0.02 | 0.02 | 0.01 | -0.07 | |
Free cash flow yield | 0.02 | -0.01 | 0.01 | 0.04 | 0.01 | |
Debt to equity | 2.13 | 2.09 | 2.16 | 2.07 | 2.19 | |
Debt to assets | 0.54 | 0.55 | 0.55 | 0.54 | 0.53 | |
Net debt to EBITDA | 19.31 | 11.65 | 11.98 | 12.03 | 89.32 | |
Current ratio | 2.24 | 2.57 | 2.46 | 2.41 | 1.81 | |
Interest coverage | 2.53 | 4.65 | 4.69 | 3.85 | 0.71 | |
Income quality | 6.29 | 0.1 | 1.36 | 4.24 | -0.38 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0.08 | 0.05 | 0.04 | 0.02 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Intangibles to total assets | 0.34 | 0.33 | 0.33 | 0.32 | 0.35 | |
Capex to operating cash flow | -0.5 | -4.88 | -0.45 | -0.31 | -0.65 | |
Capex to revenue | -0.13 | -0.06 | -0.05 | -0.08 | -0.08 | |
Capex to depreciation | -1.63 | -0.82 | -0.69 | -0.95 | -1.16 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0 | 0 | 0.01 | |
Graham number | 13.24 | 24.48 | 20.76 | 17.62 | 35.58 | |
ROIC | 0.02 | 0.03 | 0.03 | 0.03 | 0.01 | |
Return on tangible assets | 0.01 | 0.03 | 0.02 | 0.01 | -0.07 | |
Graham Net | -43.46 | -43.25 | -45.58 | -44.38 | -43.71 | |
Working capital | 375.5M | 437.5M | 453.3M | 429.4M | 295.7M | |
Tangible asset value | -225M | -195M | -207.2M | -177M | -281.4M | |
Net current asset value | -1.36B | -1.33B | -1.35B | -1.31B | -1.33B | |
Invested capital | 2.13 | 2.09 | 2.16 | 2.07 | 2.19 | |
Average receivables | 236.6M | 232.6M | 250.05M | 238.15M | 213.8M | |
Average payables | 169.7M | 174.35M | 188.75M | 200.45M | 177.85M | |
Average inventory | 308.4M | 348.2M | 374.25M | 386.9M | 348.25M | |
Days sales outstanding | 52.74 | 55.11 | 48.51 | 43.71 | 51.09 | |
Days payables outstanding | 56.55 | 59.69 | 55.73 | 56.02 | 45.66 | |
Days of inventory on hand | 108.38 | 124.05 | 105.96 | 109.79 | 89.31 | |
Receivables turnover | 1.71 | 1.63 | 1.86 | 2.06 | 1.76 | |
Payables turnover | 1.59 | 1.51 | 1.61 | 1.61 | 1.97 | |
Inventory turnover | 0.83 | 0.73 | 0.85 | 0.82 | 1.01 | |
ROE | 0.02 | 0.07 | 0.05 | 0.04 | -0.18 | |
Capex per share | -1.32 | -0.68 | -0.6 | -0.92 | -0.81 |
NGVT Frequently Asked Questions
What is Ingevity Corporation stock symbol ?
Ingevity Corporation is a US stock , located in North charleston of Sc and trading under the symbol NGVT
Is Ingevity Corporation buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $100. The lowest prediction is $100 and the highest is $100
What is NGVT stock prediction ?
What is Ingevity Corporation stock quote today ?
Ingevity Corporation stock price is $48.1 today.
Is Ingevity Corporation stock public?
Yes, Ingevity Corporation is a publicly traded company.